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CON S E N S U S S T A T EM EN T
Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date
information on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees
selection of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integ-
rity of the process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments
when such evidence is inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM member-
ship which may be incorporated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited prior
to publication. The authors are solely responsible for the content of the statements.
ACVIM consensus statement on the diagnosis of immune-
mediated hemolytic anemia in dogs and cats
Oliver A. Garden1 | Linda Kidd2 | Angela M. Mexas3 | Yu-Mei Chang4 |
Unity Jeffery5 | Shauna L. Blois6 | Jonathan E. Fogle7 | Amy L. MacNeill8 |
George Lubas9 | Adam Birkenheuer7 | Simona Buoncompagni10 |
Julien R. S. Dandrieux11 | Antonio Di Loria12 | Claire L. Fellman13 |
Barbara Glanemann4 | Robert Goggs14 | Jennifer L. Granick15 |
Dana N. LeVine16 | Claire R. Sharp17 | Saralyn Smith-Carr18 |
James W. Swann19 | Balazs Szladovits4
1School of Veterinary Medicine, University of
Pennsylvania, Philadelphia, Pennsylvania
2College of Veterinary Medicine, Western
University of Health Sciences, Pomona,
California
3College of Veterinary Medicine, Midwestern
University, Downers Grove, Illinois
4Royal Veterinary College, University of
London, London, United Kingdom
5College of Veterinary Medicine & Biomedical
Sciences, Texas A&M University, College
Station, Texas
6Ontario Veterinary College, University of
Guelph, Guelph, Ontario, Canada
Abstract
Immune-mediated hemolytic anemia (IMHA) is an important cause of morbidity and
mortality in dogs. IMHA also occurs in cats, although less commonly. IMHA is con-
sidered secondary when it can be attributed to an underlying disease, and as pri-
mary (idiopathic) if no cause is found. Eliminating diseases that cause IMHA may
attenuate or stop immune-mediated erythrocyte destruction, and adverse conse-
quences of long-term immunosuppressive treatment can be avoided. Infections,
cancer, drugs, vaccines, and inflammatory processes may be underlying causes of
IMHA. Evidence for these comorbidities has not been systematically evaluated, ren-
dering evidence-based decisions difficult. We identified and extracted data from
studies published in the veterinary literature and developed a novel tool for evalua-
tion of evidence quality, using it to assess study design, diagnostic criteria for
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IMHA, comorbidities, and causality. Succinct evidence summary statements were
written, along with screening recommendations. Statements were refined by con-
ducting 3 iterations of Delphi review with panel and task force members. Commen-
tary was solicited from several professional bodies to maximize clinical applicability
before the recommendations were submitted. The resulting document is intended
to provide clinical guidelines for diagnosis of, and underlying disease screening for,
IMHA in dogs and cats. These should be implemented with consideration of animal,
owner, and geographical factors.
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1 | INTRODUCTION
Immune-mediated hemolytic anemia (IMHA) in dogs and cats is associ-
ated with high morbidity and mortality.1–5 Pathogenic autoantibodies
target erythrocyte membrane epitopes,6,7 providing a mechanism for
fraction crystallizable receptor-mediated extravascular hemolysis medi-
ated by macrophages.8 Complement can interact with antibodies bound
to erythrocytes, facilitating extravascular hemolysis or causing intravas-
cular hemolysis by formation of the membrane attack complex. An
expeditious diagnosis that distinguishes IMHA from other causes of
anemia is critical to the rapid institution of appropriate treatment. Vari-
ous criteria for the diagnosis of IMHA have been described in the litera-
ture based on the documentation of immune-mediated erythrolysis or
proxy markers for this phenomenon,9–12 but little consensus exists on
which criteria are required for definitive diagnosis. Furthermore, the dif-
ferentiation of spontaneous IMHA from disease associated with putative
trigger factors is an important first step in the diagnostic evaluation,
because removal of trigger factors whenever possible is a crucial compo-
nent of treatment. However, no guidelines exist for the diagnostic
assessment of trigger factors, and formal assessment of the evidence
for their implication in IMHA is lacking. An evidence summary would
allow clinicians to better gauge the likelihood of a given comorbidity
being implicated in the pathogenesis of IMHA, and would help to
guide on which diagnostic tests should be performed in individual
patients.
The objective of this Consensus Statement is therefore to present
guidelines on both the fundamental diagnosis of IMHA and tests to
screen for putative trigger factors, based on evidence, inferences from
parallel data in human medicine, and expert opinion. Work contributing
to this Consensus Statement was completed by members of the Consen-
sus Panel and additional members of the relevant Veterinary and Compar-
ative Clinical Immunology Society (VCCIS) task forces established in 2015.
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2 | MATERIALS AND METHODS
2.1 | Literature review
We searched 2 databases (Medline and Web of Science) for relevant
references in April 2016 and March 2018. Standard Boolean search
terms allowing lemmatization were adopted. References captured by
the algorithm {(anemia OR anaemia) AND (dog OR cat) AND (immun*)},
hereafter denoted by A1, were imported into reference management
software (Mendeley, Elsevier, New York; EndNote X8, Clarivate Analytics,
Philadelphia), before manual screening on the basis of inclusion criteria
outlined in Supporting Information S1. The reference lists of papers also
were examined to capture references not cited on Medline or Web of
Science. Pathogen-specific searches were conducted to capture addi-
tional references (Supporting Information S1).
2.2 | Curation of records
A total of 723 papers were captured by the search algorithm A1.
Abstracts of all papers were reviewed by OAG, LK, UJ, ALM, SB, BG, RG,
and JS, leading to the rejection of 475 papers because they failed to meet
inclusion criteria. A further 67 duplicate papers were excluded, yielding
181 unique papers. Of these, an additional 118 papers were excluded
because they did not include information on patients with potential trig-
ger factors. Of the remaining 63 papers, 52 contained information of rele-
vance to infectious disease, including 14 genera of microbes infecting
dogs and 8 genera of microbes infecting cats. A pathogen-specific search
on the basis of these genera yielded 11 additional papers meeting inclu-
sion criteria. A search performed in March 2018, using both A1 and the
pathogen-specific algorithms, yielded another 6 papers. An important
paper published before the advent of online archiving was added to the
list. Data therefore were extracted from 81 papers (Figure 1).
2.3 | Quality assessment
We designed a novel quality assessment and data extraction tool,
which included domains to capture information on study design
(D) and quality (Q), confidence of comorbidity diagnosis (C), likelihood
of a causal link between comorbidity and IMHA (L), confidence of
IMHA diagnosis (I), and the number of patients with a given comorbid-
ity (N). For the purposes of this study, the term “comorbidity” included
exposure to drugs, toxins, and vaccines. Additional domains captured
detailed information on each of the comorbidities, including statistical
inferences when available. Comorbidities were summarized in 5 broad
categories: infectious disease, cancer, inflammatory disease, drugs and
toxins, and vaccines. Panel members and non-panel VCCIS task force
members were assigned to random pairings for the purpose of data
extraction and quality assessment, dividing the total number of papers
equally among all pairs. Concordance among the pairs was sought if
individual members disagreed on specific observations, and all observa-
tions relating to quality assessment were confirmed by LK and OAG.
For each comorbidity identified in a paper, an integrated metric of
evidence (IME) was computed as the sum of the normalized scores,
weighted according to our assessment of relative importance to evi-
dence rating, so long as only that comorbidity was present in individ-
ual patients, hence IME = 2D + Q + C + 2L + I + N. If >1 comorbidity
was present in individual patients, including those infected with >1
agent, an IME value was not calculated. Reference to the patients
nevertheless was made in the narrative if they yielded insight. Score
D was assessed after positing the question: Does the study ask
whether a comorbidity induces (or is associated with) IMHA as part of
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F IGURE 1 Curation of records. Papers captured by a search algorithm for anemia that met inclusion criteria (n = 248) were manually curated
to remove duplicates (n = 67), after which remaining papers were screened to assess whether they mentioned comorbidities, yielding 63 papers;
an additional 6 were added in March 2018. An independent search for infectious agents yielded an additional 11 papers of relevance. One
additional paper was identified by examining reference lists of the captured papers. IMHA, immune-mediated hemolytic anemia
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its hypothesis or specific aims, or is the question that a comorbidity
induces (or is associated with) IMHA answered by study design? If the
answer was yes, a D score was assigned; if the answer was no, the
study was designated “Descriptive Association Only” for that comor-
bidity and assigned an arbitrary D score of 1 (the lowest possible) out
of a maximum of 7. A Q score was not computed for comorbidities
assigned Descriptive Association Only, because general study quality in
those cases was irrelevant to the question of the causal relationship
between comorbidity and IMHA;Q scores in those cases were therefore 0.
The maximum normalized score for each criterion was 1, yielding a maxi-
mum IME value of 8 and a minimum of <1. An IME value of 0 was applied
when a study presented evidence against a comorbidity being associated
with IMHA. For each comorbidity within a paper, the most conservative
score for each of the IME criteria was applied for the relevant cohort of
patients, to avoid exaggeration of evidence.
Threshold IME values were computed to allow comorbidities to be
designated as negligible, low, intermediate, or high evidence for a causal
relationship with IMHA. The threshold between negligible and low evi-
dence was taken to be a hypothetical Descriptive Association Only study,
with intermediate C, L, and I scores, and 1 positive case (IME = 2.95).
The threshold between low and intermediate evidence was taken to be
a hypothetical cross-sectional study, with a Q score of 28, intermediate
C, L, and I scores, and 2-5 positive cases (IME = 4.37). Finally, the
threshold between intermediate and high evidence was taken to be a
hypothetical prospective cohort/case-control study, with a Q score of
28, high C score, intermediate L score, high I score (mechanistically
based), and 2-5 positive cases (IME = 5.78).
The quality assessment and data extraction tool is shown in Sup-
porting Information S2; Supporting Information S3 shows the deriva-
tion of each of the scores D, Q, C, L, I, and N.
2.4 | Delphi process
Each panel member drafted recommendations in assigned areas. The
draft recommendations then were subjected to 3 rounds of Delphi
review, during which each panel member was able to give written
feedback on every recommendation using an online questionnaire
(Survey Monkey, San Mateo, California). At the end of each round,
suggestions were incorporated into the working template by 1 facilita-
tor, and only recommendations for which consensus had not yet been
reached were included in the subsequent Delphi cycle. After 3 rounds
of review, unanimous consensus had been reached on the majority of
recommendations. Where differences of opinion remained, these are
indicated in the text of the Consensus Statement.
2.5 | Production of the consensus statement
OAG, LK, UJ, AMM, and SB were assigned ≥1 sections of the working
document for further editing and incorporation of comments generated
during oral presentation. These sections then were edited by the co-
Chairs, before submission to ACVIM for review by all members. The
draft Consensus Statement also was submitted to the European
College of Veterinary Internal Medicine, American College of Veterinary
Emergency and Critical Care, European College of Veterinary Emergency
and Critical Care, the American College of Veterinary Pathology, and the
European College of Veterinary Clinical Pathology for solicitation of com-
ments from members. Feedback from these specialist colleges was used
by the panel members to produce the final Consensus Statement.
3 | DIAGNOSIS OF IMMUNE-MEDIATED
HEMOLYTIC ANEMIA
No agreed diagnostic gold (criterion) standard exists for IMHA in veteri-
nary patients, similar to the situation in humans. The British Society for
Hematology's guidelines for diagnosis of autoimmune hemolytic anemia
(AIHA) recommend the direct antiglobulin test (DAT) in patients with
hemolysis, but also emphasize that the test is neither specific nor 100%
sensitive for AIHA.13 The diagnostic tests described below therefore
should be interpreted in combination with the results of other diagnostic
tests and response to immunosuppression. The lack of a gold (criterion)
standard also presents challenges when interpreting the literature. For
example, although sensitivities and specificities are discussed here (either
as reported directly in the referenced studies, or calculated by the panel
using data within the reference), the criteria used to define cases as posi-
tive or negative for IMHA vary. Variability also exists in how tests are
performed and validated, and therefore performance in 1 study may not
generalize to others.
Cognizant of these caveats, 7 of 8 panel members considered the
algorithm in Figure 2 appropriate for diagnosis of primary or second-
ary IMHA, complemented by the following explanatory notes. (One
panel member considered that markers of immune-mediated disease
should be assessed with caution in the absence of hemolysis.) This
discussion is restricted to immune-mediated destruction of circulating
erythrocytes (ie, precursor-targeted immune-mediated anemia or pure
red cell aplasia are not discussed). Readers requiring additional infor-
mation on immune-mediated differentiation failure or destruction at
the level of the bone marrow are referred elsewhere.14–17
3.1 | Anemia
A spun PCV is suggested because calculated hematocrit may be unreli-
able when agglutination is present.18–20 However, studies in humans
have reported increased plasma trapping by abnormal erythrocytes
(eg, spherocytes), which could introduce inaccuracy into the spun
PCV.21 To the best of our knowledge, the effect of agglutination or
spherocytosis on spun PCV has not been investigated in veterinary
species. Lack of regeneration (as assessed by reticulocyte count) does
not eliminate IMHA because approximately 30% of dogs have non-
regenerative anemia at presentation.5,22
3.2 | Signs of immune-mediated destruction
3.2.1 | Prominent spherocytosis
Spherocytes should be used as a diagnostic criterion only in dogs because
feline erythrocytes do not consistently display central pallor. Interpreting
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spherocytes after blood transfusion should be done cautiously, because
stored blood products may contain high proportions of spherocytes23
and spherocytes have been documented in human patients with hemo-
lytic transfusion reactions.24,25 Spherocytosis should be assessed in the
monolayer of a well-made blood smear, because spherocyte-like artifacts
arise toward the feathered edge and in thick areas.26 In anemic animals,
spherocytes should be confirmed in the deeper monolayer to avoid arti-
facts in thin areas. Spherocytosis also can induce increased osmotic
fragility,27,28 but because osmotic fragility testing is influenced by other
factors (eg, hyperlipidemia,27 erythrocyte age29), the panel does not advo-
cate its routine use in the diagnosis of IMHA.
Reported causes of non-immune-mediated spherocytes, or morphologi-
cally similar pyknocytes, should be eliminated, including oxidative damage
(eg, zinc30,31 and acetaminophen32), envenomation,33–37 hypersplenism (eg,
hepatosplenic lymphoma),38 pyruvate kinase deficiency,39 disorders associ-
ated with erythrocyte fragmentation (eg, endocarditis,40 microangiopathic
hemolytic disorders including hemangiosarcoma,41 or hemolytic uremic
syndrome),42 and dyserythropoiesis.43 Hereditary spectrin deficiency also
potentially may give rise to spherocytes if smears are made from blood
stored >24 hours.44 The percentage of spherocytes on blood smears from
human patients with mutations causing hereditary spherocytosis is vari-
able, but can be high.45 A literature search for canine hereditary sphero-
cytosis did not identify any cases with marked spherocytosis.
In a single study, ≥5 spherocytes/×100 oil immersion field yielded
63% sensitivity (95% confidence interval [CI], 39%-84%) (when 95%
CIs were not provided by the authors, the online MedCalc Diagnostic
F IGURE 2 Diagnostic algorithm for immune-mediated hemolytic anemia (IMHA). Having identified anemia in a patient, biomarkers of
immune-mediated destruction should next be assessed, including the saline agglutination test (SAT), direct antiglobulin test (DAT), and/or flow
cytometry (FC); at least 2 should be present, or a positive SAT that persists with washing, to make a firm diagnosis of IMHA. Signs of hemolysis
should then be assessed, at least 1 of which should be present for a firm diagnosis. Variations on this theme would yield a supportive or
suspicious diagnosis, provided another cause of anemia is not identified. Additional abbreviations: ≥, at least; dz, disease
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test evaluation calculator [https://www.medcalc.org/calc/diagnostic_
test.php] was used to calculate them) and 95% specificity (95% CI,
76%-100%) for IMHA in dogs,27 compared with 74% sensitivity (95% CI,
49%-91%) and 81% specificity (95% CI, 59%-95%)c for ≥3/×100 oil
immersion field.27 A threshold of ≥5 spherocytes/×100 oil immersion
field therefore could be considered supportive of a diagnosis of IMHA,
but 3-4 spherocytes/×100 oil immersion field also may be consistent
with IMHA provided no other cause of spherocytosis is identified. These
thresholds are similar to the criteria for 1+ spherocytosis in a proposed
semiquantitative grading system.46 Where spherocyte numbers are low
(versus their typical abundance in extravascular IMHA), variability among
fields could be an issue: calculating mean count over several fields
(eg, 10) could help establish the true extent of spherocytosis. For
enrollment of cases in IMHA research, only high-quality blood smears
should be used, and given the pitfalls of spherocyte recognition, examina-
tion of the smears by a board-certified clinical pathologist is advantageous.
3.2.2 | Positive saline agglutination test
Although evaluation of dried blood smears or hematology instrument
scatter plots20 can suggest agglutination, the panel does not consider
these techniques adequate to confirm agglutination based on the possi-
bility of overlapping rouleaux on blood smears and the potential for other
causes of macrocytes on scattergram evaluation.47 Saline agglutination
testing performed by mixing 4 drops of saline with 1 drop of blood has a
reported specificity of 100% (95% CI, 95%-100%)c for IMHA in dogs.27
Mixing blood and saline 1:1 yielded a specificity of 95% (95% CI, 88%-
99%)c based on 85 dogs without IMHA, or 85% (95% CI, 65%-96%)c
when only anemic dogs were considered.11 Agglutination that persists
after mixing 1 drop of blood with 4 drops of saline therefore is
considered adequate evidence for agglutination in most cases.27 Consid-
erably higher dilution ratios can aid the microscopic identification of
agglutination. To decrease false positives, confirming that agglutination
persists after washing erythrocytes 3 times in a 1:4 ratio with saline11 is
recommended for animals with equivocal results (eg, rare small erythro-
cyte clumps in an otherwise negative test), markedly increased total pro-
tein (eg, leishmaniasis, multiple myeloma, and feline infectious peritonitis
[FIP]) or fibrinogen concentrations,48 or strong rouleaux formation on
blood smear examination. Based on reports of agglutination of washed
erythrocytes from normal dogs at 4C, we suggest that the saline solution
should be between room temperature and 37C.49
3.2.3 | Demonstration of anti-erythrocyte antibodies
Five panel members preferred the direct Coombs' test (DAT) and
3 considered flow cytometry and DAT to be equally useful. Supporting
Information S4 provides recommendations for performance of these
tests. If the DAT cannot be performed because agglutination persists
after washing, the combination of anemia, hemolysis, and persistent
agglutination is sufficient for diagnosis of IMHA. Immunochromatogra-
phy offers an alternative to conventional DAT or flow cytometry, but
confirming negative results by conventional DAT may be advisable
because of frequent weak positive test strips in DAT-positive dogs.11
For DAT, sensitivity ranged from 61 to 82% for dogs27,50 and 82%
for cats51 for studies reported between 2006 and 2016 that did not
rely on DAT alone for the diagnosis of IMHA and reported sensitivity
or sufficient information for its calculation. Specificity for DAT was
94%-100% for dogs11,27,50,52 and 95%-100% for cats9,51,53 for studies
published between 2006 and 2016 that reported specificity or suffi-
cient information for its calculation. Although small experimental stud-
ies have reported sensitivities of up to 100% for flow cytometry,54–57
sensitivity was 67% (95% CI, 53%-79%)c in a larger study reporting
results of routine clinical testing.58 For studies including clinically ill
negative controls, specificity for flow cytometry was 87.5% (95% CI,
47%-100%)c54 to 92% (95% CI, 88%-95%)c.56
Reports of sample handling effects on flow cytometry are lacking.
Storage of samples at 4C for up to 7 days before DAT testing is
acceptable unless the laboratory advises otherwise.11 Current data,
although limited, suggest that although immunosuppression does not
immediately result in a negative DAT,11,59 interindividual variability
exists in the time required to become negative DAT after initiation of
treatment.11,60 For flow cytometry, anecdotal reports suggest that
immunosuppression decreases the percentage of antibody-positive
erythrocytes.56 Therefore, where possible, we recommend collection
of samples for DAT or flow cytometry before initiation of treatment.
Large-scale studies of the effect of prior blood transfusion on DAT or
flow cytometry are lacking. Based on reports of DAT-negative results
for 21 dogs posttransfusion,11 prior blood transfusion is not an abso-
lute contraindication for testing. However, a positive DAT has been
reported in a dog without signs of IMHA but with a history of multiple
transfusions.61 Furthermore, delayed serological or hemolytic transfu-
sion reactions with positive DAT are reported in humans.62–64 There-
fore, where possible, we recommend collection of samples for DAT
before blood transfusion.
A suggested advantage of flow cytometry compared with DAT is the
generation of a more quantitative result, potentially allowing monitoring
of therapeutic success. Statistical associations are reported between labo-
ratory or clinical features and the percentage of antibody-positive eryth-
rocytes.56,58 However, the clinical value of the percentage of positive
erythrocytes has not been evaluated rigorously.56
3.3 | Evidence of hemolysis
3.3.1 | Spherocytosis
In dogs, spherocytes (assessed as described) can provide evidence of
hemolysis, consistent with evidence of this phenomenon in human
erythrocytes.65,66 The increased rigidity of spherocytes results in entrap-
ment within the spleen and subsequent extravascular hemolysis.28,67,68
3.3.2 | Hyperbilirubinemia
In the absence of decreased functional hepatic mass, obstructive chole-
stasis, or sepsis, hyperbilirubinemia may represent evidence of hemolysis.
At least 1 of the following is considered sufficient evidence for hyperbi-
lirubinemia: icterus, total serum or plasma bilirubin concentration above
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reference interval, bilirubinuria in cats, or ≥2+ bilirubin on a urine reagent
strip in dogs. Bilirubin reported for hemolyzed samples should be inter-
preted in combination with information regarding the likely impact of
hemolysis on the assay.69
3.3.3 | Hemoglobinemia/Hemoglobinuria
Hemoglobinemia can be detected by visual examination of plasma or
measurement of cell-free hemoglobin. When using instrument-based
indicators of hemolysis, limitations of the individual method should be
considered. For example, spectrophotometric hemolytic indices rely on
manufacturer-specific methods and algorithms that are not directly com-
parable among different instruments.70 Similarly, discrepancy between
mean cell hemoglobin concentration and cellular hemoglobin concentra-
tion provided by ADVIA hematology instruments may reflect hemolysis
or other sample characteristics, such as lipemia.71
Hemoglobinemia should only be interpreted as evidence of hemo-
lysis after eliminating artifactual hemolysis. Common causes of in vitro
hemolysis include, but are not limited to, traumatic venipuncture,72–75
freezing, storage, and (based on studies in humans) sampling via an IV
catheter72,76,77 or post-collection injection of samples into vacutai-
ners.78 The likelihood of in vitro hemolysis is increased if factors that
increase erythrocyte fragility are present (eg, lipemia).79 Provided
causes of myoglobinuria are absent, hemoglobinuria is considered pre-
sent if urine is red and discoloration is not cleared by centrifugation, or
if a positive heme reaction on urine dipstick is present in the absence
of intact erythrocytes on microscopic sediment examination. Assess-
ment of hemoglobinuria should be performed using a fresh urine sam-
ple, and anecdotally the likelihood of erythrocyte lysis in urine is
increased in alkaline or poorly concentrated or hyposthenuric urine
samples.
3.3.4 | Erythrocyte ghosts
Ghost cells provide evidence of intravascular hemolysis if seen on a
smear made immediately after blood collection.3,80
4 | PUTATIVE TRIGGER FACTORS
4.1 | Infectious disease
Recent evidence suggests that any infection can trigger immune dys-
regulation, loss of immune tolerance, and development of immune-
mediated disease in an individual patient with a genetic, epigenetic, or
susceptible microenvironmental milieu at the time of infection.81–86
However, certain organisms may cause specific immune-mediated dis-
eases. Examples in people include Mycoplasma pneumoniae infection
causing IMHA and Helicobacter pylori causing immune-mediated
thrombocytopenia.87,88 Other mechanisms such as circulating immune
complex deposition and activation of immune cells through fraction
crystallizable receptor engagement or delivery of immunoglobulin-
bound nucleic acid to Toll-like receptors also occur during some infec-
tions.89 Damage to target cells is another mechanism that may make a
pathogen particularly likely to induce autoimmunity by increased
exposure of self-epitopes that normally are sequestered or ineffi-
ciently presented to immune cells.81,90 This proposed mechanism for
the development of IMHA91 contributes to the accelerated clearance
of erythrocytes during Plasmodium infection in people and mice.92 It
also may occur during Babesia gibsoni infection in dogs and Myco-
plasma haemofelis infection in cats.93–97 Antibody-mediated removal
is part of normal erythrocyte senescence.98 Organisms thus may
cause IMHA by amplifying normal antibody-mediated removal of aged
or damaged erythrocytes.
4.1.1 | Consensus Summary Statement
Organisms identified in this review with a high and an intermediate
level of evidence as a cause of IMHA are likely to induce disease by a
mechanism that can trigger immune-mediated erythrocyte destruction
in many patients. Further study is required to determine the role of
other infections in IMHA. We emphasize that, for most studies, a low
level of evidence represents a lack of studies designed to answer
whether an infection is associated with IMHA, rather than studies that
specifically demonstrated a lack of evidence. In addition, environmen-
tal, genetic, and epigenetic factors play a role in whether immune-
mediated disease occurs in an individual patient. Therefore, clinicians
should consider the possibility that any identified recent or recurrent
infection may contribute to the development of IMHA. Furthermore,
eliminating the possibility of infection is prudent before immunosup-
pressive treatment.
4.1.2 | Summary of evidence
Overall, 66 manuscripts were reviewed.3,9,10,12,27,51,57,94–97,99–153 The
IME values were calculated for 27 infectious agents or types of infec-
tion (Figures 3–5), but could not be calculated for many infectious
agents either because of the way data were summarized (eg, the num-
ber of individual patients with IMHA and an infection could not be
discerned) or because an individual patient with IMHA had >1 comor-
bidity (Supporting Information S2). In addition, most investigators did
not specifically ask whether infection causes IMHA. Consensus Sum-
mary Statements are presented here for all genera of organisms for
which at least 1 study had an intermediate or higher level of evidence
that infection induced IMHA. All additional organisms are discussed in
Supporting Information S5.
4.2 | Infections in dogs
4.2.1 | Piroplasms
Seventeen studies documented 103 cases of IMHA in Babesia-infected
dogs.57,93–96,99,102–104,111,120,122,128,134,141,147,151 The IME values for
Babesia species as a whole ranged from 0.00 to 6.99, with a median of
4.55. Fifty-three percent (10/19) of the IME values demonstrated an
intermediate or high level of evidence that Babesia causes IMHA. For
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3 additional studies, the number of dogs with Babesia and IMHA could
not be determined.105,125,136
There is a high level of evidence that immune-mediated destruc-
tion of erythrocytes contributes to anemia in dogs infected with
B. gibsoni. Immune-mediated hemolytic anemia was documented in
69 dogs in 9 studies,93–96,99,102,103,111,151 with an additional study (in
which the number of infected dogs with IMHA could not be deter-
mined) providing useful mechanistic insight.125 The median IME value
was 5.32, ranging from 2.54 to 6.99. For this Babesia species, 88%
(8/9) of the studies showed intermediate (4) or high (4) IME values.
Four were studies of dogs experimentally infected with B. gibsoni,
yielding a median IME value of 6.41 and range of 6.08-6.99.94–96,99
Natural infection with B. gibsoni occurs most commonly in fighting
breeds.102,125 However, mixed breed dogs used in experimental studies
also develop IMHA, suggesting that the immune-mediated pathogenesis
is largely driven by the parasite.99
Whether other species of Babesia cause IMHA in dogs remains
unclear. One study documented IMHA in 2 chronically infected
splenectomized mixed breed dogs experimentally infected with
what was thought to be B. gibsoni, but later characterized as Babesia
conradae,147 yielding an IME value of 6.25. Five studies documented
13 cases of IMHA in dogs infected with Babesia canis, with a median
IME value of 3.20 and range of 0-4.32.57,104,111,128,134 Babesia vogeli
was documented in 2 studies of 5 dogs with IMHA, with IME values of
5.73 and 4.14. Five cases of IMHA were documented in a study of
Babesia rossi-infected dogs, although the authors presumed a Babesia
species based on cytological examination of blood smears and geo-
graphic locale.120 The IME value was 2.56. In an additional study, the
F IGURE 3 Integrated metric
of evidence (IME) summary for all
comorbidity categories. Horizontal
dotted lines indicate the threshold
IME values between negligible and
low (2.95), low and intermediate
(4.37), and intermediate and high
(5.78) levels of evidence. Most
IME values fell within the
negligible and low zones of
evidence, while a small number
were 0, indicating evidence against
that comorbidity inducing
immune-mediated hemolytic
anemia (IMHA). No studies of
relevance to vaccination as a
potential trigger for IMHA in cats
could be found
F IGURE 4 Integrated metric of evidence (IME) values for infectious agents and diseases in dogs. Horizontal dotted lines indicate the threshold
IME values between negligible and low (2.95), low and intermediate (4.37), and intermediate and high (5.78) levels of evidence. spp, species
(plural term)
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Babesia species was not specified, but again was likely to be B. rossi.122
Nine dogs with IMHA were documented in that study, with an IME
value of 2.70. Thus, the evidence for large Babesia species causing
IMHA is lower than that for B. gibsoni, attributed in part to the fact that
most studies were not designed to determine if an association between
IMHA and infection existed. Nevertheless, differences also may exist
in pathogenicity among Babesia species that influence the risk of
IMHA. For example, 1 study found that the majority of anemic
B. vogeli-infected dogs had IgM and IgG bound to erythrocytes, but
these antibodies were not detected in dogs infected with B. canis.57
In this study, eccentrocytosis, suggesting oxidative damage, was
more common in B. canis-infected dogs. The IME value for B. canis in
this study was 0, whereas it was 5.73 for B. vogeli.57
The mechanism of immune-mediated erythrocyte destruction dur-
ing B. gibsoni infection has been explored. Because Babesia species
infect erythrocytes, antibodies appropriately targeting the organisms
could result in “immune-mediated” erythrocyte destruction without tar-
geting self-antigen. However, antibodies produced during infection also
appear to target erythrocyte membranes. Oxidative injury may play a
role in anti-erythrocyte antibody formation.96 Activated macrophages
cause oxidative damage to uninfected as well as infected erythrocytes
during B. gibsoni infection, a factor that may contribute to the severity
of IMHA in some dogs.96 In addition to oxidative damage, sialic acid
residue removal is required to expose epitopes that are targeted by
antibody.94 Interestingly, anti-erythrocyte antibodies that developed in
dogs experimentally infected with B. gibsoni did not attach to unda-
maged red blood cells in dogs that had recovered from clinical infec-
tion.93 Furthermore, in vitro studies have shown that Babesia-induced
antibody reactivity against erythrocytes is higher for aged and oxidized
than for fresh erythrocytes.95 Taken together, these data suggest that
ongoing damage to the red cell membrane and increased exposure of
epitopes that are usually “hidden” facilitates immune-mediated erythro-
cyte destruction. Once infection is controlled, the drive for immune-
mediated destruction stops.
Like Babesia species, Rangelia and Theileria species are protozoan
parasites that infect erythrocytes in dogs. A study of dogs experimen-
tally infected with Rangelia vitelli demonstrated that a regenerative
anemia suspicious for IMHA developed in infected dogs.149 Treatment
of infection resolved the anemia without immunosuppression. A ret-
rospective case series of dogs naturally infected with Theileria spp.
developed IMHA.137 Dogs were treated with combined immunosup-
pression and imidocarb dipropionate. The authors reported resolution
of hematological abnormalities during an unspecified study period.
The IME values could not be calculated, because the total number of
dogs with IMHA could not be discerned.
Consensus Summary Statement
The evidence that piroplasms, and in particular B. gibsoni, cause IMHA
is intermediate to high. For B. gibsoni, evidence suggests that during
infection, antibodies target host erythrocyte antigens exposed as a
consequence of transient oxidative damage or sialic acid residue removal.
Further study is needed to determine if differences in pathogenicity
among species, host factors, or both mediate risk of development of
IMHA in infected dogs. What is known about the mechanism of erythro-
cyte destruction suggests that immunosuppression should not be neces-
sary to resolve immune-mediated erythrocyte destruction in most cases.
4.2.2 | Anaplasma species
Nine dogs with IMHA in 5 studies were infected with, or exposed to,
Anaplasma phagocytophilum.101,108,126,129,150 The median IME value
was 3.53, with a range of 2.62-4.25. In addition to IMHA, platelet-
bound antibodies were documented in some dogs with concurrent
thrombocytopenia.101,108 Although most dogs in these reports were
treated concurrently with doxycycline and immunosuppressive cortico-
steroid treatment, 1 dog responded to doxycycline treatment alone,150
whereas another dog had prednisone discontinued after 2 days.108 One
retrospective case series documented 2 dogs with acute Anaplasma
platys infections with concurrent IMHA.100 Both dogs had spherocyto-
sis and positive saline agglutination and Coombs' test results supporting
the diagnosis of IMHA. The IME value for this study was 3.76.
Consensus Summary Statement
The evidence that A. phagocytophilum causes IMHA is low. However,
most studies reporting A. phagocytophilum in dogs with IMHA were
limited to case reports or retrospective studies, and were not designed
to investigate a causal relationship. The presence of IMHA and other
immune-mediated conditions concurrent with this infection suggests
that prospective controlled studies to examine a possible causal rela-
tionship between A. phagocytophilum and IMHA in dogs are warranted.
The evidence that A. platys induces IMHA in dogs is low, but data are
limited to a single retrospective case series. Further prospective, con-
trolled studies are required to document a possible causal relationship
between A. platys and IMHA in dogs.
Evidence that other vector-borne agents (including Dirofilaria
immitis, Ehrlichia spp. Borrelia spp., hemotropic Mycoplasma spp.,
Bartonella spp., and Leishmania infantum), non-vector-borne proto-
zoal pathogens (including Neospora caninum), and other bacterial
infections induce IMHA was negligible to low (Figure 4), or could not
be quantified based on how results were reported (Supporting Infor-
mation S5).105,109,125,137,145 For some of these organisms, such as
Leishmania spp., D. immitis, and Bartonella spp., Coombs' test-positive
anemia is observed commonly with infection.105,109,145 Therefore,
from a clinical perspective, it is still important to eliminate infection
with these agents in a dog in which IMHA is a differential diagnosis.
4.3 | Infections in cats
4.3.1 | Babesia felis
Immune-mediated hemolytic anemia was documented in 9 of 56 cats
infected with B. felis in 1 study from South Africa. Six of the 9 cats
were coinfected with feline leukemia virus (FeLV).138 Treatment for
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B. felis without immunosuppression resolved IMHA, yielding an IME
value of 4.98.
Consensus Summary Statement
Although studies are limited, an intermediate level of evidence was
found that B. felis causes IMHA in cats, and that treatment resolves
IMHA without immunosuppression.
4.3.2 | HemotropicMycoplasma species
Seven studies documenting IMHA in 21 cats infected with hemotropic
Mycoplasma spp. yielded IME values.3,51,97,110,130,140,153 The median
IME value was 2.37, but values differed widely among hemotropic
Mycoplasma species, ranging from 0 to 6.78. Overall, a high level of
evidence exists for M. haemofelis inducing IMHA in cats. Immune-
mediated hemolytic anemia was documented in 15 cats in 3 studies
for this species.3,97,140 The median IME value was 6.10, with a range
of 2.37-6.78. Two of the 3 studies provided high evidence97,140; the
other study was not designed to answer whether infection causes
IMHA.3 In a study of cats experimentally infected with M. haemofelis,
severe macrocytic Coombs' test-positive anemia and persistent auto-
agglutination of erythrocytes developed. In contrast, these findings
did not occur when cats were infected with the less pathogenic
Candidatus (Ca.) Mycoplasma haemominutum and Ca. Mycoplasma
turicensis species.140 The target of anti-erythrocyte antibody that
develops during M. haemofelis infection in cats was investigated in
1 study.97 Serum from cats infected with M. haemofelis agglutinated
infected and neuraminidase-treated erythrocytes but not normal
erythrocytes, suggesting that, as in babesiosis, damage to erythrocytes
and unmasking of antigens contribute to the pathogenesis of IMHA.97
Ca. M. haemominutum infection was documented in 3 cats with IMHA
over 4 studies (1 study showing no associationwith IMHA),3,51,130,140 yield-
ing amedian IME value of 2.16 and range of 0-4.2.
Consensus Summary Statement
A high level of evidence was found that M. haemofelis causes IMHA in
cats. Negligible to low level of evidence was found that the less patho-
genic species Ca. M. haemominutum causes IMHA, and no evidence was
found that Ca. M. turicensis induces IMHA. Whether coinfection and host
immune status play roles in development of IMHA in cats infected with
different hemotropicMycoplasma species requires further study.
4.3.3 | Viral infections
Feline leukemia virus
Seven studies meeting inclusion criteria were identified.3,9,110,119,138,153,154
However, other comorbidities such as erythroleukemia, myeloproliferative
disease, chronic interstitial nephritis, glomerulonephritis and splenic amy-
loidosis, and drug administration were documented in some infected cats,
precluding IME calculation.110,138,153,154 The median IME value for the
otherswas 3.77,with a range of 1.87-5.04.3,9,110,119,153,154
Consensus Summary Statement
Collectively, the evidence that FeLV infection induces IMHA is low.
The observation that some FeLV-positive cats also have Coombs'
test-positive anemia should prompt further investigation into whether
immune-mediated erythrocyte destruction can contribute to anemia
in FeLV-positive cats.
Summaries of the evidence for other infections that have been
documented in cats with IMHA, including FIP, feline immunodefi-
ciency virus (FIV), L. infantum, Mycoplasma gatae, M. haemofelis, soft
tissue infection, and urinary tract infection are provided in Supporting
Information S6.
5 | CANCER
5.1 | Cancer in dogs
Immune-mediated hemolytic anemia is a recognized paraneoplastic
syndrome in people.155–158 Chronic lymphocytic leukemia is a well-
established cause of IMHA in people.155,156 Other neoplasms have
been associated with IMHA in humans, but the causal mechanisms
remain elusive.157,158 The IME values could be calculated for 13 stud-
ies (Figure 6). The global median IME value was 1.87, with a range
from 1.70 to 3.12, thus representing levels of evidence that were neg-
ligible (29 IME values; 70 patients) or low (3 IME values; 3 patients).
The generally low level of evidence reflects the fact that the majority
of the published studies did not specifically ask whether cancer is
F IGURE 5 Integrated metric of evidence (IME) values for
infectious agents and diseases in cats. Horizontal dotted lines indicate
the threshold IME values between negligible and low (2.95), low and
intermediate (4.37), and intermediate and high (5.78) levels of
evidence. Ca., Candidatus; FeLV, feline leukemia virus; FIP, feline
infectious peritonitis; FIV, feline immunodeficiency virus; Hem.,
hemotropic; M.,Mycoplasma
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associated with canine IMHA, or if they did, were associated with low
Q scores.
Two individual studies yielded low level evidence. The first described
a mast cell tumor in a dog with IMHA, with an IME value of 3.12, and a
pheochromocytoma in a dog with concurrent IMHA and immune-
mediated thrombocytopenia, with an IME value of 3.12.116 The sec-
ond, a case report of an undifferentiated sarcoma in a Flat-Coated
Retriever with IMHA, postulated that the sarcoma was a trigger for the
IMHA, with an IME value of 3.17.159 Mycoplasma haemocanis was
identified in a splenectomized dog with cytological and clinical charac-
teristics of acute lymphocytic leukemia.139 Although the development
of IMHA in this dog was attributed to the hemotropic Mycoplasma
infection, involvement of the leukemia could not be excluded. A canine
IMHA patient with a duodenal leiomyosarcoma had an IME value of
1.70.10 Three further patients with hemangiosarcoma and IMHA were
described, for which the IME value was 1.87.2 A number of other
papers yielded a negligible level of evidence for neoplasia as a cause
of IMHA. These documented the presence of carcinomas,2,10,12
malignant histiocytosis, and other hematopoietic tumors,134 myeloid
neoplasia,2,10,132,134,160 multiple myeloma,161 sarcomas,2,10 and mis-
cellaneous undefined tumors2,10,134,142,143,162,163 in dogs with IMHA.
Consensus Summary Statement
Evidence of a causal link between cancer and IMHA in dogs currently is
lacking in the veterinary literature, largely reflecting the fact that
the majority of the published studies did not specifically ask whether
cancer was associated with IMHA in dogs. Further studies are needed
to determine if such an association exists. Although no evidence for a
causal link exists, cancer cannot be eliminated as a potential trigger for
this disease.
5.2 | Cancer in cats
Five studies reported 21 cats with neoplasia and IMHA (Figure 7).
These studies provide negligible evidence for a causal link between
neoplasia and IMHA, yielding a median IME value of 1.87 and a range
of 1.7-4.4. No study specifically addressed this hypothesis. In a single
retrospective study of 107 cats with IMHA, concurrent neoplasia was
present in 16 (15%) cats.3
5.2.1 | Hematopoietic and lymphoid neoplasia
Eight cats for which an IME value could be calculated for lymphoma
and IMHA were identified.3,9,164 Two of the 3 studies reporting these
cases did not demonstrate a causal association between IMHA and
lymphoma,3,9 and 1 study was considered to partially report or sug-
gest causality.164 The latter reports 2 sibling specific pathogen-free
experimental cats. For both cats, lymphoma/lymphocytic leukemia
was diagnosed on histological review after necropsy. However, inter-
pretation of the histology in both cats was equivocal. The histological
pattern was described as multicentric T-lymphoblastic infiltration with
associated B-lymphocyte proliferation, which the authors concluded
was most likely a lymphoproliferative disorder, but they did not elimi-
nate an aberrant immune response. For 1 cat, the diagnosis of
F IGURE 6 Integrated metric of evidence (IME) values for cancer
types in dogs. Horizontal dotted lines indicate the threshold IME
values between negligible and low (2.95), low and intermediate (4.37),
and intermediate and high (5.78) levels of evidence. Miscellaneous
cancer types included pheochromocytoma, unspecified abdominal,
adrenal, bladder, cardiac, mediastinal, and splenic masses, other
hematopoietic tumors, and unspecified neoplasia. Lym., lymphoid;
Myeloid, myeloid leukemia or myeloproliferative disease
F IGURE 7 Integrated metric of evidence (IME) values for cancer
types in cats. Horizontal dotted lines indicate the threshold IME
values between negligible and low (2.95), low and intermediate (4.37),
and intermediate and high (5.78) levels of evidence. Miscellaneous
cancer types included gastrointestinal and uncharacterized neoplasia.
Lym., lymphoid; Myeloid, myeloid leukemia or myeloproliferative
disease
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lymphoma/lymphocytic leukemia was made within 3 weeks of the
onset of IMHA, and no other potential trigger for secondary IMHA
was described. For the second cat, 2 episodes of IMHA were
described, 1 potentially associated with an experimental herpes virus
infection and the other potentially associated with experimental FeLV
infection. For the other 2 studies, neither the method of diagnosis nor
the subtype of lymphoma was specified. The evidence for a causal
association between IMHA and lymphoma is low, with a median IME
value of 3.54 and a range of 1.87-4.24.
A single cat with multiple myeloma and IMHA was identified.3 This
study did not show a causal association between neoplasia and IMHA,
and the method of diagnosis of neoplasia was unclear. The evidence
for an association between IMHA and multiple myeloma was negligi-
ble, with an IME value of 1.70.
Three cats with erythroleukemia3,153 and 3 cats with non-specified
myeloproliferative disease110 and IMHA were identified. No study dem-
onstrated a causal association between IMHA and neoplasia. The report
of 2 of the cats with erythroleukemia suggests that diagnosis was based
on bone marrow cytological or histological review, or both.3 The method
of diagnosis of neoplasia was not described for the third cat with ery-
throleukemia.153 For the cats with non-specified myeloproliferative dis-
ease, the diagnosis was based on bone marrow examination, but details
are limited.110 All cats with non-specified myeloproliferative disease
were FeLV positive.110 The evidence for a causal association between
erythroleukemia and IMHA is negligible, with an IME value for the
1 study in which it could be assigned of 1.87.3 Other studies of erythro-
leukemia or unspecified myeloproliferarative disease did not yield IME
values because of the presence of comorbidities.
A single cat with histiocytic sarcoma and IMHA was identified.3
This study did not show a causal association between IMHA and neo-
plasia, and the method of diagnosis of neoplasia was not described,
yielding an IME value of 1.70.
5.2.2 | Solid tumors
A single case of pancreatic carcinoma110 and a single case of anaplas-
tic sarcoma3 with giant cells in cats with IMHA were identified. Nei-
ther study showed a causal association between IMHA and neoplasia.
The evidence for a causal association between IMHA and carcinoma,
and sarcoma, was negligible, with an IME value of 1.70 in each case.
5.2.3 | Miscellaneous and minimally described
neoplasia
One cat with IMHA and uncharacterized gastrointestinal neoplasia51 and
6 cats with IMHA and uncharacterized masses3 were identified. A causal
association between IMHA and these lesions was not identified. The
method of diagnosis for the presumed neoplastic lesions was not
described. The evidence for a causal association between IMHA and
uncharacterized gastrointestinal neoplasia is low, with an IME value of
3.92, and negligible for uncharacterizedmasses, with an IME value of 2.04.
Consensus Summary Statement
Currently, no strong evidence exists for a causal link between cancer
and IMHA in cats; further studies are needed to determine if such an
association exists. Nevertheless, retrospective evidence suggests a
relatively high prevalence of concurrent cancer in cats with IMHA.
6 | INFLAMMATORY DISEASE
6.1 | Pancreatitis in dogs and cats
Inflammation that often occurs with IMHA could indirectly lead to
pancreatitis by activation of neutrophils or formation of thromboem-
boli. Subsequent oxidative damage, ischemic events, or both then may
directly damage the pancreas. Alternatively, inflammation associated
with pancreatitis could lead to IMHA by indirectly inducing autoanti-
bodies to form against erythrocytes. Autoantibodies that bind to epi-
topes on both exocrine pancreatic epithelium and erythrocytes also
may be generated.165 To date, none of these hypotheses has been
confirmed in veterinary species. Observation of concurrent pancrea-
titis and IMHA has been reported in an 8-year-old female Cocker
Spaniel166 and in some retrospective studies of dogs with IMHA
(Figure 8). Studies that evaluated groups of dogs with IMHA indi-
cate that the prevalence of concurrent pancreatitis is low, between
1% (1/93 IMHA dogs142) and 5% (1/19 dogs10). Both of these stud-
ies yielded an IME value for pancreatitis of 1.70.10,142 The Cocker
Spaniel in the case report had both IMHA and pancreatitis.166 How-
ever, cholestasis and renal failure also were present. Although chole-
stasis and renal failure can be complications of pancreatitis, primary
organ disease could not be eliminated, precluding calculation of an
IME value.
A recent study of 11 cats with IMHA showed that 3 of these cats
(3/11; 27.3%) had pancreatitis,165 yielding an IME value of 3.99. This
study was designed to answer the question of whether IMHA is asso-
ciated with pancreatitis.165 Another large study of cats with IMHA
indicated that 6/107 (5.6%) had concurrent cholangitis, pancreatitis, or
both.3 An IME value could not be calculated because information regard-
ing the number of cats with pancreatitis alone was not specified.
Consensus Summary Statement
The evidence for pancreatitis causing IMHA is negligible in dogs and
negligible to low in cats. Additional studies would be required to estab-
lish a causal relationship.
6.2 | Necrosis in dogs
One study attributed secondary IMHA to concurrent liver necrosis12
and another to concurrent necrotizing inflammation of the tail,2 both
in single patients; both studies yielded an IME value of 1.70. Further
evaluation of these patients was not pursued.
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Consensus Summary Statement
The evidence for necrosis as a cause of IMHA is negligible in dogs and
is not reported in cats.
6.3 | Other sources of inflammation in dogs and cats
Reports of other inflammatory processes were identified in several
reports. Two studies reported 4 dogs with IMHA that were diagnosed
with systemic lupus erythematosus.2,167 Other reported inflammatory
diseases in dogs with IMHA included 3 dogs with gastroenteritis,
2 dogs with dermatitis,2 and 1 dog each with hepatitis,143 rheumatoid
arthritis,10 and mesenteric lymphadenitis.2 Negligible evidence was
found for these inflammatory conditions inducing IMHA, with a median
IME value of 1.70 and a range of 1.70-1.95. Seven of 107 (6.5%) cats
with IMHA had clinical evidence of inflammation or infection that was
not further classified, yielding an IME value of 2.04.2
Consensus Summary Statement
Anecdotal reports suggest that generalized inflammatory processes
induce IMHA in dogs and cats, but direct evidence is lacking. Well-
designed studies to determine whether non-infectious inflammatory
processes cause IMHA are warranted.
7 | DRUGS AND TOXINS
7.1 | Dogs
Seventeen studies described dogs with IMHA that had been exposed
to drugs or toxins,1,10,12,27,34,80,116,127,135,142,143,160,168–172 but only
11 reported cases with sufficient primary data for the calculation of
an IME value.10,12,27,34,80,142,143,168–170,172 The majority of cases (35/36)
were dogs exposed to antimicrobial drugs.10,80,142,143,168,170 For these
cases, IME values ranged from 1.70 to 7.09, with a median of 1.87
(Figure 9). The highest level of evidence, with an IME value of 7.09, came
from 1 unblinded, randomized, prospective clinical trial in which 6 of
14 dogs given escalating doses of cefazedone acquired anti-erythrocyte
antibodies.168 The remaining reported cases were associated with low or
negligible evidence to support other drugs or toxins as a cause for IMHA
in dogs (Figure 9).
7.2 | Cats
Two papers describe the development of IMHA after administration of
propylthiouracil to cats, with respective IME values of 7.33 and 4.19. In
the first study of 105 cats, 7 cats with hyperthyroidism treated with pro-
pylthiouracil developed immune-mediated drug reactions.173 This finding
was followed by a prospective, un-blinded, non-randomized trial in which
17 healthy cats were given the same drug, causing 9 to develop Coombs'
test-positive anemia.174 One additional case report describes warfarin
exposure in a cat with IMHA, with an IME value of 1.70.110
Consensus Summary Statement
The prevalence of drug-induced IMHA in dogs and cats is either rare
or underreported. However, a lack of evidence does not preclude the
possibility of a drug or toxin triggering IMHA.
8 | VACCINES
8.1 | Dogs
The most effective vaccines elicit robust immune responses only
against the pathogen of interest. However, vaccines also may elicit
unfavorable immune responses resulting from mechanisms such as
molecular mimicry, bystander cell activation, or downregulation of
self-tolerance, which contribute to autoimmunity.175,176 For dogs,
32 papers mentioned that vaccines could be a trigger for IMHA, of
which only 12 papers describe 79 clinical cases with documented tem-
poral associations of ≤30 days between vaccine administration and
IMHA.5,22,80,107,116,143,170,177–181 The types of vaccines given to each
F IGURE 8 Integrated metric
of evidence (IME) values for
inflammatory diseases. Horizontal
dotted lines indicate the threshold
IME values between negligible and
low (2.95), low and intermediate
(4.37), and intermediate and high
(5.78) levels of evidence. infl'n,
inflammation; SLE, systemic lupus
erythematosus
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patient were not consistently recorded. Seven papers provide negligible
primary case data linking vaccination and IMHA.22,80,116,143,170,180,181
Three papers provide evidence for a link between vaccination and
IMHA in the low range, with IME values between 2.95 and
4.37.5,177,178 No publications that provide high levels of evidence to
support an association between vaccination and IMHA were found.
Two studies reported intent to evaluate an association between vac-
cines and IMHA. In 1 retrospective study, associated with an IME
value of 5.76, a difference was found in the frequency of IMHA cases
diagnosed within the first month after vaccination and those diag-
nosed at subsequent months, whereas a similar temporal distribution
was not identified in a control group.179 A subsequent study had a
similar Q score, but showed no difference in the number of cases with
recent vaccination history between the IMHA and control groups, and
therefore was awarded an IME value of 0.107
Other papers we reviewed excluded patients with a recent vacci-
nation history, with the intent of describing only dogs with idiopathic
IMHA.182–185 In addition, some papers did not include the vaccination
status of dogs with IMHA.56,101,161,186,187 Other data we excluded
from analysis included studies with an uncertain diagnosis of
IMHA,188,189 case studies in which alternative causes of IMHA were
possible,171,190 and cases from studies in which the timing of vaccina-
tion was not specified.16 Only 1 study prospectively investigated a
link between vaccination and autoimmune disease in 5 dogs, demon-
strating the presence of autoantibodies after vaccine administration.
However, these dogs only were followed for 21 days after vaccination
and did not meet the criteria for diagnosis of IMHA.191 With only
2 papers in the veterinary literature aiming to evaluate a link between
vaccination and IMHA, and each of these respectively supporting179
or refuting107 an association, the question of whether vaccines trigger
IMHA in dogs remains unanswered. Similarly, insufficient evidence is
available to determine whether vaccination triggers autoimmune dis-
ease in people.192 No reports of an association between vaccine
administration and IMHA in cats were found.
Consensus Summary Statement
Considering the wide practice of vaccination and lack of conclusive evi-
dence of an association with IMHA, current vaccination strategies
generally are safe. Patients should be individually assessed for their
own risks and benefits before vaccination. Further studies are needed to
determine if and when vaccine-associated IMHA occurs in dogs and cats,
and to develop better methods for the diagnosis of vaccine-associated
disease.
9 | GLOBAL SCREENING
RECOMMENDATIONS
9.1 | Optimal minimum database (dogs and cats)
9.1.1 | Consensus Summary Statement
A thorough history documenting vaccination, travel, exposure to fleas
and ticks, flea and tick prevention, and heartworm testing and preven-
tion is recommended. A thorough physical examination including retinal
examination should be performed. Laboratory screening should include
a CBC, blood film examination by a board-certified clinical pathologist
(or equivalently trained hematologist), serum biochemical profile, and
routine urinalysis. Urine culture and fecal flotation with centrifugation
also should be considered. Abdominal radiographs are important to elimi-
nate hemolysis caused by zinc toxicity. Imaging and other diagnostic
tests to screen for cancer remain a reasonable component of a diagnostic
evaluation for IMHA in dogs and cats, performed at the discretion of the
attending clinician on the basis of the likelihood of cancer in the individ-
ual patient. Routine testing for pancreatitis in dogs and cats with IMHA
is not recommended, unless clinical presentation suggests that it is a
credible differential diagnosis.
9.1.2 | Rationale
History will help assess the likely risk of certain infections. A thorough
physical examination and diagnostic imaging will help identify any
potential nidus of infection or the presence of neoplastic lesions. Pat-
terns of abnormalities identified on the CBC, serum biochemistry, and
urinalysis can increase the index of suspicion for specific infectious
agents that may be associated with IMHA.193–202 This minimum data-
base also can identify additional pathological processes (eg, protein-
uria) that may require specific treatment. Although insensitive, blood
F IGURE 9 Integrated metric of
evidence (IME) values for drugs.
Horizontal dotted lines indicate the
threshold IME values between
negligible and low (2.95), low and
intermediate (4.37), and
intermediate and high (5.78) levels
of evidence. The single
antimicrobial drug yielding high-
level evidence in dogs was
cefazedone. NSAID, non-steroidal
anti-inflammatory drug
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smear examination can be useful in identifying the presence of
vector-borne disease agents. Although the evidence associated with
urinary tract infection as a cause of IMHA is negligible, identification
and treatment of infection before immunosuppression is prudent. We
refer the reader to the ACVIM consensus statement on the treatment
of IMHA (in press) for further recommendations and additional discus-
sion on the specific circumstance of treating subclinical bacteriuria in
an immunosuppressed patient. The evidence that gastrointestinal par-
asites cause IMHA in dogs is low, but rapid resolution of IMHA with
treatment and minimal immunosuppression has been described
(Supporting Information S5).121 Imaging will help identify neoplasia
or a nidus of infection.
9.2 | Testing for infectious agents in dogs
9.2.1 | Consensus Summary Statement
Dogs with IMHA should be screened for infection with Babesia spp.
using combined testing with serology and polymerase chain reaction
(PCR). Repeat testing by means of PCR should be performed in all
dogs originally testing negative but with a high risk of infection based
on breed or exposure risk. The sensitivity of PCR and serological test-
ing may vary depending on the laboratory and test design. Infection
with other piroplasms, including Rangelia and Theileria species, should
be eliminated in endemic areas. Because D. immitis infection is associ-
ated with anemia and positive Coombs' test results, all dogs should be
screened for D. immitis in endemic areas or when travel to such areas
has occurred. Further study to determine how and if other vector-
borne disease agents cause IMHA is required before definitive screen-
ing recommendations can be made for additional organisms. However,
screening for additional vector-borne pathogens, in particular Ana-
plasma spp., Bartonella spp., Ehrlichia spp., and, in endemic areas, Leish-
mania spp., should be strongly considered. Potential foci of other
infections identified during initial screening should be further investi-
gated at the discretion of the attending clinician.
9.2.2 | Rationale
The evidence that Babesia spp. induce IMHA is intermediate to high.
Infection with B. gibsoni should be ruled out. Transmission of B. gibsoni in
fighting breeds is through bite wounds and vertical transmission.102,203
However, tick transmission by Haemaphysalis spp. and possibly Rhipice-
phalus sanguineus can occur, and experimental infection of mixed breed
dogs results in IMHA.99,204–208 Therefore, screening for B. gibsoni in all
breeds with IMHA is prudent. B. vogeli should be ruled out in dogs with a
history of exposure to R. sanguineus. Retired racing Greyhound dogs are
at increased risk of infection because of the common occurrence of
R. sanguineus infestations in racing kennels.102,193,209 Testing for B. canis
and B. rossi by means of serology and PCR should be performed in
endemic areas. Dogs living in California and Coyote hunting dogs
specifically should be screened for B. conradae by means of PCR
(no serological test is available).210,211 Although evidence of causation
is lacking, Coombs' test-positive anemia is commonly documented
in dogs with heartworm disease, bartonellosis, and leishmaniosis
(Supporting Information S5).105,109,145 General principles for optimal
use of serology and PCR in diagnosing vector-borne disease are sum-
marized in Supporting Information S7. Generally, combining PCR with
serological testing enhances sensitivity.212–214 Repeat testing, includ-
ing repeating PCR on the same or additional samples, and pairwise
serological testing to demonstrate a 4-fold change between acute and
convalescent titers, also are necessary to document infection in many
cases.212–217
9.3 | Testing for infectious agents in cats
9.3.1 | Consensus Summary Statement
Polymerase chain reaction testing for B. felis should be performed in
cats from endemic areas and in those with suggestive clinical signs.
Serological testing was not available at the time of writing, but com-
bined testing would be optimal based on studies of Babesia species
infecting dogs. Polymerase chain reaction testing for M. haemofelis
should be performed in all cats with IMHA. Further studies are
needed to determine whether infection with other hemotropic Myco-
plasma species is associated with IMHA in immunosuppressed or coin-
fected cats. Testing for all 3 species is preferred when possible. All
sick cats should be tested for FeLV and FIV infection, according to
American Association of Feline Practitioners retrovirus management
guidelines (https://www.catvets.com/guidelines/practice-guidelines/
retrovirus-management-guidelines), screening all cats with IMHA for
FeLV using antigen ELISA. Proviral FeLV DNA quantitative PCR test-
ing may be helpful as a confirmatory test. Routine testing for feline
coronavirus and non-hemotropic Mycoplasma spp. in cats with IMHA
is not recommended, but appropriate diagnostic tests should be con-
sidered in cats with compatible clinical signs.
9.3.2 | Rationale
Identification of Babesia spp. by light microscopy of blood smears is con-
sidered insensitive for screening in cats. Polymerase chain reaction to
identify parasitic DNA or RNA is recommended.218 A high level of evi-
dence was found that M. haemofelis causes IMHA in cats. Coinfection
and host immune status may play a role in the development of IMHA in
cats infected with the less pathogenic hemotropic Mycoplasma spp. In
addition, coinfection with multiple hemotropic Mycoplasma species is
common.51,144 Therefore, infection with a less pathogenic species may
signal that repeat testing forM. haemofelis is warranted. Non-hemotropic
Mycoplasma infection only has been described in 1 cat with IMHA.148
However,M. pneumoniae causes cold agglutinin hemolytic anemia in peo-
ple, and infection with Mycoplasma cynos was associated with develop-
ment of cold agglutinins in a dog.135 Therefore, it should be considered as
a possible trigger in cats with IMHA and other findings compatible with
infection. The evidence for FeLV in association with IMHA in cats is
negligible to intermediate. Polymerase chain reaction testing for proviral
DNA could be considered as part of infectious disease screening. The
overall evidence that FIP induces IMHA is negligible. However, given
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the immune mechanisms underlying effusive FIP, testing for FIP in cats
with compatible clinical and laboratory findings is judicious.
9.4 | Drug and vaccine administration in dogs
and cats
9.4.1 | Consensus Summary Statement
There is insufficient evidence to recommend withholding necessary
medications for dogs and cats with IMHA. However, all medications,
particularly those previously implicated in immune-mediated diseases,
should be used with caution in patients with IMHA. Every patient
should ideally have a complete history recorded, which includes all
vaccines and drugs administered, the doses, dates, frequency, dura-
tion, and route of their administration, and information about the
products being used such as manufacturer, indications, specific lot,
and any adverse events. Exposure to toxins should also be documen-
ted in any dog or cat with IMHA.
9.4.2 | Rationale
Evidence for cefazedone in dogs168 and propylthiouracil in cats173,174
suggests that >1 class of drugs may be associated with IMHA in small
animals. For most commonly prescribed medications, the evidence is
negligible. Specific documentation of vaccine histories and long-term
prospective studies may help determine whether vaccines can trigger
IMHA. To date, approximately 8% of dogs with a diagnosis of IMHA
and vaccination histories had been vaccinated within 30 days of
IMHA diagnosis. However, studies comparing this prevalence to ade-
quate controls are limited and inconclusive. Animals with IMHA are at
risk for recurrence of anemia, making careful decisions about the risks
and benefits of revaccinating important in every case. Animals receiv-
ing immunosuppressive treatment are less likely to mount protective
immunity after routine vaccination.
10 | ICEBERG MODEL AND PROPOSED
NEW NOMENCLATURE
Based on the data analyzed here, we propose a unified model for the
pathogenesis of IMHA and a new system of nomenclature, in which
the disease is categorized as “non-associative” and “associative” rather
than “primary” and “secondary,” respectively (Figure 10A,B). This clari-
fication is needed because the word “primary” implies that all triggers
have been definitively ruled out, whereas “secondary” implies causa-
tion. We propose that the term “associative” be used when a comor-
bidity is identified. In some cases, the comorbidity might have caused
the IMHA (secondary IMHA), whereas in others it might be coinciden-
tal (primary IMHA). “Non-associative” IMHA cases are those in which
comorbidities are not identified in the diagnostic evaluation, and
include primary (“idiopathic”) and cryptogenic cases. The latter implies
that an underlying cause was not identified, perhaps because the
underlying pathomechanisms are not currently understood, or the
comorbidity could not be detected using available testing.
11 | FUTURE RESEARCH DIRECTIONS
When the VCCIS task forces were formed, we began by identifying a
focused question that represented an important problem in veterinary
immunology, namely “What is the evidence that infection, neoplasia,
drugs, vaccines, and other comorbidities cause IMHA in dogs and
cats?” Our original intent was to perform a systematic review of the
literature to answer this question. However, it quickly became appar-
ent that very few studies in the veterinary literature were designed to
determine if a given comorbidity causes IMHA, hence an expanded
approach was used to evaluate the evidence presented in our review.
There is a critical need for well-designed, prospective, case-controlled
clinical studies that directly ask the question of whether infections,
neoplasia, drugs, and vaccines cause IMHA. Some comorbidities are
likely to cause IMHA in a large number of affected patients, such as
an infection that expresses an epitope mimicking an erythrocyte anti-
gen widely expressed in a population, or an organism that causes
(A)
(B)
F IGURE 10 Iceberg model and proposed new nomenclature for
immune-mediated hemolytic anemia (IMHA). A, The iceberg model
posits that pathomechanisms underlying IMHA fall on a spectrum,
both recognized (above the water level) and currently unrecognized or
occult (concealed), the latter postulated to be the majority.
Hypothetical occult pathomechanisms are listed. B, We propose a
new nomenclature for IMHA to better reflect the heterogeneity in
pathomechanisms underlying IMHA
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transient expression of normally hidden epitopes. Others might induce
IMHA only in patients with epigenetic and genetic predisposition, or a
given inflammatory context. Studies that investigate how individual
comorbidities trigger IMHA, and the role of genetics and epigenetics,
will help identify what diseases to screen for in all patients, and what
diseases to screen for in selected patients that may be at increased
risk of developing IMHA from any trigger. Mechanistic studies also
will determine which comorbidities, when treated, will lead to resolu-
tion of IMHA without the need for immunosuppression. Stringent cri-
teria for the diagnosis of IMHA and definitive diagnosis of a comorbidity
must be integrated into study design in order to make meaningful
observations.
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